SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

被引：0

作者：

Efe, Cumali ^{[1
]}

Tascilar, Koray ^{[2
,3
]}

Gerussi, Alessio ^{[4
,5
,6
]}

Bolis, Francesca ^{[4
,5
]}

Lammert, Craig ^{[7
]}

Ebik, Berat ^{[8
]}

Stattermayer, Albert Friedrich ^{[9
]}

Cengiz, Mustafa ^{[10
]}

Gokce, Dilara Turan ^{[11
]}

Cristoferi, Laura ^{[4
,5
,6
]}

Peralta, Mirta ^{[12
,13
]}

Massoumi, Hatef ^{[14
]}

Montes, Pedro ^{[15
]}

Cerda, Eira ^{[16
]}

Rigamonti, Cristina ^{[17
,18
]}

Yapali, Suna ^{[19
]}

Adali, Gupse ^{[20
]}

Caliskan, Ali Riza ^{[21
]}

Balaban, Yasemin ^{[22
]}

Eren, Fatih ^{[23
]}

Eskazan, Tugce ^{[24
]}

Barutcu, Sezgin ^{[25
]}

Lytvyak, Ellina ^{[26
,27
]}

Zazueta, Godolfino Miranda ^{[28
]}

Kayhan, Meral Akdogan ^{[10
]}

Heurgue-Berlot, Alexandra ^{[29
]}

De Martin, Eleonora ^{[30
]}

Yavuz, Ahmet ^{[31
]}

Biyik, Murat ^{[31
]}

Narro, Graciela Castro ^{[28
]}

Duman, Serkan ^{[32
]}

Hernandez, Nelia ^{[33
]}

Gatselis, Nikolaos K. ^{[34
,35
,36
]}

Aguirre, Jonathan ^{[37
]}

Idilman, Ramazan ^{[32
]}

Silva, Marcelo ^{[13
,38
]}

Mendizabal, Manuel ^{[13
,38
]}

Atay, Kadri ^{[39
]}

Guzelbulut, Fatih ^{[40
]}

Dhanasekaran, Renumathy ^{[41
]}

Montano-Loza, Aldo J. ^{[26
,27
]}

Dalekos, George N. ^{[34
,35
,36
]}

Ridruejo, Ezequiel ^{[13
,38
,42
]}

Invernizzi, Pietro ^{[4
,5
,6
]}

Wahlin, Staffan ^{[43
,44
]}

机构：

[1] Harran Univ Hosp, Dept Gastroenterol, Sanliurfa, Turkey

[2] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Med Rheumatol & Immunol 3, Erlangen, Germany

[3] Univ Klinikum Erlangen, Erlangen, Germany

[4] Univ Milano Bicocca, Div Gastroenterol, Dept Med & Surg, Monza, Italy

[5] Univ Milano Bicocca, Ctr Autoimmune Liver Dis, Dept Med & Surg, Monza, Italy

[6] San Gerardo Hosp, European Reference Network Hepatol Dis ERN RARE L, Monza, Italy

[7] Univ Sch Med, Dept Med Indiana, Indianapolis, IN USA

[8] Gazi Yasargil Educ & Res Hosp, Dept Gastroenterol, Diyarbakir, Turkey

[9] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria

[10] Gulhane Training & Res Hosp, Dept Gastroenterol, Ankara, Turkey

[11] Ankara City Hosp, Dept Gastroenterol, Ankara, Turkey

[12] Hosp Francisco J Muniz, Hepatol Sect, Buenos Aires, DF, Argentina

[13] Latin Amer Liver Res Educ & Awareness Network LAL, Pilar, Argentina

[14] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA

[15] Hosp Nacl Daniel A Carrion, Gastroenterol & Hepatol Unit, Callao, Peru

[16] Hosp Mil Cent Mexico, Hepatol Unit, Ciudad De Mexico, Mexico

[17] Univ Piemonte Orientale UPO, Dept Translat Med, Novara, Italy

[18] AOU Maggiore della Carita, Div Internal Med, Novara, Italy

[19] Acibadem Univ, Dept Gastroenterol, Sch Med, Istanbul, Turkey

[20] Umraniye Educ & Res Hosp, Dept Gastroenterol, Istanbul, Turkey

[21] Adiyaman Univ, Dept Gastroenterol, Adiyaman, Turkey

[22] Hacettepe Univ, Fac Med, Dept Gastroenterol, Ankara, Turkey

[23] Uludag Univ, Med Fac, Dept Gastroenterol, Bursa, Turkey

[24] Cerrahpa Sch Med, Dept Gastroenterol, Istanbul, Turkey

[25] Univ Gaziantep Med Fac, Dept Gastroenterol, Gaziantep, Turkey

[26] Univ Alberta, Div Gastroenterol, Edmonton, AB, Canada

[27] Univ Alberta, Liver Unit, Edmonton, AB, Canada

[28] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Gastroenterol Unit, Ciudad De Mexico, Mexico

[29] CHU Reims, Dept Hepatogastroenterol, Reims, France

[30] Univ Paris Saclay, Ctr Hepatobiliaire, INSERM Unit UMR 1193, FHU Hepatinov,Hop Paul Brousse, Paris, France

[31] Necmettin Erbakan Univ, Meram Sch Med, Div Gastroenterol, Konya, Turkey

[32] Ankara Univ, Dept Gastroenterol, Med Fac, Ankara, Turkey

[33] Univ Republica, Hosp Clin, Fac Med, Gastroenterol & Hepatol Unit, Montevideo, Uruguay

[34] Gen Univ Hosp Larissa, Natl Expertise Ctr Greece Autoimmune Liver Dis, Dept Med, Larisa, Greece

[35] Gen Univ Hosp Larissa, Natl Expertise Ctr Greece Autoimmune Liver Dis, Res Lab Internal Med, Larisa, Greece

[36] Gen Univ Hosp Larissa, European Reference Network Hepatol Dis ERN RARE L, Larisa, Greece

[37] Hosp Ngeles Pedregal, Hepatol Unit, Ciudad De Mexico, Mexico

[38] Hosp Univ Austral, Hepatol & Liver Transplant Unit, Pilar, Argentina

[39] Mardin State Hosp, Dept Gastroenterol, Mardin, Turkey

[40] Haydarpa Numune Educ & Res Hosp, Dept Gastroenterol, Istanbul, Turkey

[41] Stanford Univ, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA

[42] CEMIC, Ctr Educ Med & Invest Clin, Hepatol Sect, Dept Med, Buenos Aires, DF, Argentina

[43] Karolinska Inst, Dept Upper GI Dis, Hepatol Div, Stockholm, Sweden

[44] Karolinska Univ Hosp, Stockholm, Sweden

来源：

JOURNAL OF AUTOIMMUNITY | 2022年 / 132卷

关键词：

Liver failure; Breakthrough infection; Immunosuppression; Vaccine; Autoimmunity;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in pa-tients with AIH.

引用

页数：5

共 50 条

[21] The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: A meta-analysis
Ao, Guangyu
Li, Toni
Wang, Yushu
Tran, Carolyn
Gao, Ming
Chen, Min
JOURNAL OF INFECTION, 2023, 86 (02) : E43 - E45
[22] SARS-CoV-2 and COVID-19
Sheng, Wang-Huei
Ko, Wen-Chien
Huang, Yhu-Chering
Hsueh, Po-Ren
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (03) : 363 - 364
[23] SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
Duengelhoef, Paul
Hartl, Johannes
Ruether, Darius
Steinmann, Silja
Brehm, Thomas T.
Weltzsch, Jan Philipp
Glaser, Fabian
Schaub, G. M.
Sterneck, Martina
Sebode, Marcial
Weiler-Normann, Christina
Addo, Marylyn M.
Luetgehetmann, Marc
Haag, Friedrich
Schramm, Christoph
zur Wiesch, Julian Schulze
Lohse, Ansgar W.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2022, 10 (03) : 319 - 329
[24] Risk for severe outcomes of COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany
Sorg, Anna-Lisa
Hufnagel, Markus
Doenhardt, Maren
Diffloth, Natalie
Schroten, Horst
von Kries, Rudiger
Berner, Reinhard
Armann, Jakob
EUROPEAN JOURNAL OF PEDIATRICS, 2022, 181 (10) : 3635 - 3643
[25] Risk for severe outcomes of COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany
Anna-Lisa Sorg
Markus Hufnagel
Maren Doenhardt
Natalie Diffloth
Horst Schroten
Rüdiger von Kries
Reinhard Berner
Jakob Armann
European Journal of Pediatrics, 2022, 181 : 3635 - 3643
[26] COVID-19 vaccination: Effects of immunodominant peptides of SARS-CoV-2
de Andrade, Arthur Gomes
Comberang, Fernando Cezar
Cavalcante-Silva, Luiz Henrique Agra
Kessen, Tatjana Souza Lima
CYTOKINE, 2023, 170
[27] Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
Yamada, Shinya
Asakura, Hidesaku
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
[28] COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections
Maple, Peter A. C.
VACCINES, 2023, 11 (02)
[29] Severe autoimmune hepatitis following recovery from COVID-19: a novel mode of liver injury triggered by SARS-COV-2?
Folman, Adam
Said-Ahmad, Helal
Mari, Amir
Saadi, Tarek
Veitsman, Ella
Yaccob, Afif
MINERVA GASTROENTEROLOGY, 2022, 68 (03): : 334 - 336
[30] Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrough COVID-19 During Omicron Wave in Patients with Autoimmune Diseases
Connolly, Caoilfhionn
Wallwork, Rachel
Chiang, Teresa Po-Yu
Teles, Mayan
Alejo, Jennifer
Massie, Allan
Shah, Ami
Albayda, Jemima
Christopher-Stine, Lisa
Segev, Dorry
Werbel, William
Paik, Julie
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4528 - 4530

← 1 2 3 4 5 →